Profiling tofersen as a treatment of superoxide dismutase 1 amyotrophic lateral sclerosis

References

• Feldman EL, Goutman SA, Petri S, et al. Amyotrophic lateral sclerosis. Lancet. 2022;400(10360):1363–1380. doi: 10.1016/S0140-6736(22)01272-7
   PubMed Web of Science ®Google Scholar
• Hardiman O, Al-Chalabi A, Chio A, et al. Correction: amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3(1):17085. doi: 10.1038/nrdp.2017.85
   PubMedGoogle Scholar
• Xu L, Liu T, Liu L, et al. Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol. 2020;267(4):944–953. doi: 10.1007/s00415-019-09652-y
   PubMed Web of Science ®Google Scholar
• Suzuki N, Nishiyama A, Warita H, et al. Genetics of amyotrophic lateral sclerosis: seeking therapeutic targets in the era of gene therapy. J Hum Genet. 2023;68(3):131–152. doi: 10.1038/s10038-022-01055-8
   PubMed Web of Science ®Google Scholar
• Goutman SA, Hardiman O, Al-Chalabi A, et al. Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurol. 2022;21(5):465–479. doi: 10.1016/S1474-4422(21)00414-2
   PubMed Web of Science ®Google Scholar
• Zou ZY, Zhou ZR, Che CH, et al. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2017;88(7):540–549. doi: 10.1136/jnnp-2016-315018
   PubMed Web of Science ®Google Scholar
• Renton AE, Chiò A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17(1):17–23. doi: 10.1038/nn.3584
   PubMed Web of Science ®Google Scholar
• Aoki M, Ogasawara M, Matsubara Y, et al. Mild ALS in Japan associated with novel SOD mutation. Nat Genet. 1993;5(4):323–324. doi: 10.1038/ng1293-323
   PubMed Web of Science ®Google Scholar
• Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362(6415):59–62. doi: 10.1038/362059a0
   PubMed Web of Science ®Google Scholar
• Deng HX, Hentati A, Tainer JA, et al. Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science. 1993;261(5124):1047–1051. doi: 10.1126/science.8351519
   PubMed Web of Science ®Google Scholar
• Bernard E, Pegat A, Svahn J, et al. Clinical and molecular landscape of ALS patients with SOD1 mutations: novel pathogenic variants and novel phenotypes. A single ALS center study. Int J Mol Sci. 2020;21(18):6807. doi: 10.3390/ijms21186807
   PubMed Web of Science ®Google Scholar
• Bunton-Stasyshyn RK, Saccon RA, Fratta P, et al. SOD1 function and its implications for amyotrophic lateral sclerosis pathology: new and renascent themes. Neuroscientist. 2015;21(5):519–529. doi: 10.1177/1073858414561795
   PubMed Web of Science ®Google Scholar
• Kaur SJ, McKeown SR, Rashid S. Mutant SOD1 mediated pathogenesis of Amyotrophic Lateral Sclerosis. Gene. 2016;577(2):109–118. doi: 10.1016/j.gene.2015.11.049
   PubMed Web of Science ®Google Scholar
• Sau D, De Biasi S, Vitellaro-Zuccarello L, et al. Mutation of SOD1 in ALS: a gain of a loss of function. Hum Mol Genet. 2007;16(13):1604–1618. doi: 10.1093/hmg/ddm110
   PubMed Web of Science ®Google Scholar
• Ekhtiari Bidhendi E, Bergh J, Zetterström P, et al. Mutant superoxide dismutase aggregates from human spinal cord transmit amyotrophic lateral sclerosis. Acta Neuropathol. 2018;136(6):939–953. doi: 10.1007/s00401-018-1915-y
   PubMed Web of Science ®Google Scholar
• Aoki M, Abe K, Houi K, et al. Variance of age at onset in a Japanese family with amyotrophic lateral sclerosis associated with a novel Cu/Zn superoxide dismutase mutation. Ann Neurol. 1995;37(5):676–679. doi: 10.1002/ana.410370518
   PubMed Web of Science ®Google Scholar
• Saeed M, Yang Y, Deng HX, et al. Age and founder effect of SOD1 A4V mutation causing ALS. Neurology. 2009;72(19):1634–1639. doi: 10.1212/01.wnl.0000343509.76828.2a
   PubMed Web of Science ®Google Scholar
• Bali T, Self W, Liu J, et al. Defining SOD1 ALS natural history to guide therapeutic clinical trial design. J Neurol Neurosurg Psychiatry. 2017;88(2):99–105. doi: 10.1136/jnnp-2016-313521
   PubMed Web of Science ®Google Scholar
• Berdynski M, Miszta P, Safranow K, et al. SOD1 mutations associated with amyotrophic lateral sclerosis analysis of variant severity. Sci Rep. 2022;12(1):103. doi: 10.1038/s41598-021-03891-8
   PubMed Web of Science ®Google Scholar
• Arisato T, Okubo R, Arata H, et al. Clinical and pathological studies of familial amyotrophic lateral sclerosis (FALS) with SOD1 H46R mutation in large Japanese families. Acta Neuropathol. 2003;106(6):561–568. doi: 10.1007/s00401-003-0763-5
   PubMed Web of Science ®Google Scholar
• Benatar M, Wuu J. Presymptomatic studies in ALS: rationale, challenges, and approach. Neurology. 2012;79(16):1732–1739. doi: 10.1212/WNL.0b013e31826e9b1d
   PubMed Web of Science ®Google Scholar
• Benatar M, Wuu J, Lombardi V, et al. Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(7–8):538–548. doi: 10.1080/21678421.2019.1646769
   PubMed Web of Science ®Google Scholar
• Benatar M, Wuu J, Andersen PM, et al. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol. 2018;84(1):130–139. doi: 10.1002/ana.25276
   PubMed Web of Science ®Google Scholar
• Miller T, Cudkowicz M, Shaw PJ, et al. Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2020;383(2):109–119. doi: 10.1056/NEJMoa2003715
   PubMed Web of Science ®Google Scholar
• Doble A. The pharmacology and mechanism of action of riluzole. Neurology. 1996;47(6 Suppl 4):S233–41. doi: 10.1212/WNL.47.6_Suppl_4.233S
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole study group. N Engl J Med. 1994;330(9):585–591. doi: 10.1056/NEJM199403033300901
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. amyotrophic lateral sclerosis/riluzole study group II. Lancet. 1996;347(9013):1425–1431. doi: 10.1016/S0140-6736(96)91680-3
   PubMed Web of Science ®Google Scholar
• Andrews JA, Jackson CE, Heiman-Patterson TD, et al. Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(7–8):509–518. doi: 10.1080/21678421.2020.1771734
   PubMed Web of Science ®Google Scholar
• Mandrioli J, Malerba SA, Beghi E, et al. Riluzole and other prognostic factors in ALS: a population-based registry study in Italy. J Neurol. 2018;265(4):817–827. doi: 10.1007/s00415-018-8778-y
   PubMed Web of Science ®Google Scholar
• Traynor BJ, Alexander M, Corr B, et al. An outcome study of riluzole in amyotrophic lateral sclerosis–a population-based study in Ireland, 1996-2000. J Neurol. 2003;250(4):473–479. doi: 10.1007/s00415-003-1026-z
   PubMed Web of Science ®Google Scholar
• Writing Group On Behalf Of The Edaravone Als 18 Study G. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: grade 3, requiring assistance for eating, excretion or ambulation). Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(sup1):40–48. doi: 10.1080/21678421.2017.1361441
   PubMedGoogle Scholar
• Takahashi F, Takei K, Tsuda K, et al. Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(sup1):32–39. doi: 10.1080/21678421.2017.1361442
   PubMed Web of Science ®Google Scholar
• Writing G; Edaravone; (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505–512. doi: 10.1016/S1474-4422(17)30115-1
   PubMed Web of Science ®Google Scholar
• Paganoni S, Macklin EA, Hendrix S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383(10):919–930. doi: 10.1056/NEJMoa1916945
   PubMed Web of Science ®Google Scholar
• Paganoni S, Hendrix S, Dickson S, et al. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve. 2021;63(1):31–39. doi: 10.1002/mus.27091
   PubMed Web of Science ®Google Scholar
• Blair HA. Tofersen: first approval. Drugs. 2023;83(11):1039–1043. doi: 10.1007/s40265-023-01904-6
   PubMed Web of Science ®Google Scholar
• Miller TM, Cudkowicz ME, Genge A, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2022;387(12):1099–1110. doi: 10.1056/NEJMoa2204705
   PubMed Web of Science ®Google Scholar
• Wiesenfarth M, Dorst J, Brenner D, et al. Effects of tofersen treatment in patients with SOD1-ALS in a “real-world” setting - a 12-month multicenter cohort study from the German early access program. EClinicalMedicine. 2024;69:102495. doi: 10.1016/j.eclinm.2024.102495
   PubMedGoogle Scholar
• Tofersen, in drugs and lactation database (LactMed(r)). Bethesda (MD); 2006. https://www.ncbi.nlm.nih.gov/sites/books/NBK592200/
   Google Scholar
• Thouvenot E, Demattei C, Lehmann S, et al. Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis. Eur J Neurol. 2020;27(2):251–257. doi: 10.1111/ene.14063
   PubMed Web of Science ®Google Scholar
• Benatar M, Wuu J, Andersen PM, et al. Design of a randomized, placebo-controlled, phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers: the ATLAS study. Neurotherapeutics. 2022;19(4):1248–1258. doi: 10.1007/s13311-022-01237-4
   PubMed Web of Science ®Google Scholar
• Marriott H, Kabiljo R, Hunt GP, et al. Unsupervised machine learning identifies distinct ALS molecular subtypes in post-mortem motor cortex and blood expression data. Acta Neuropathol Commun. 2023;11(1):208. doi: 10.1186/s40478-023-01686-8
   PubMed Web of Science ®Google Scholar
• Maragakis NJ, de Carvalho M, Weiss MD. Therapeutic targeting of ALS pathways: Refocusing an incomplete picture. Ann Clin Transl Neurol. 2023;10(11):1948–1471. doi: 10.1002/acn3.51887
   PubMed Web of Science ®Google Scholar